Clinical development is the stage of drug or medical device creation where a potential treatment is tested in people for the first time. It sits between laboratory research and regulatory approval, and it’s where scientists determine whether something that worked in a lab actually works safely in human beings. This process typically unfolds across multiple phases, each with a distinct purpose, and it represents the most expensive and time-consuming part of bringing a new treatment to market.
Where Clinical Development Fits in the Bigger Picture
The FDA breaks drug development into five steps: discovery, preclinical research, clinical research, FDA review, and post-market safety monitoring. Clinical development is step three. Before it begins, a compound has already been identified as promising and tested in animals to get a rough sense of its safety. After it ends, the data collected goes to regulators who decide whether to approve it.
To move from animal testing into human trials, a company must file an Investigational New Drug (IND) application with the FDA. This filing includes animal safety data, manufacturing details, and detailed plans for the proposed human studies. Once submitted, the company must wait 30 calendar days before enrolling a single patient, giving the FDA time to review the application and flag any concerns that could put participants at unreasonable risk.
The Four Phases of Clinical Trials
Phase 1: Safety First
A new drug enters human testing in a small group of 20 to 80 people, often healthy volunteers rather than patients with the disease. The goal is straightforward: figure out whether the drug is safe enough to keep testing. Researchers look for side effects, study how the body absorbs and processes the compound, and determine what dose range seems reasonable. These trials are tightly monitored and carefully escalated.
Phase 2: Does It Work?
If Phase 1 goes well, the drug moves to trials involving 100 to 300 people who actually have the condition the drug is meant to treat. This is the first real test of effectiveness. Researchers are also still watching for side effects, but the central question shifts: does this drug do what we think it does? Many drugs fail here because they turn out to be less effective than lab results suggested.
Phase 3: Confirmation at Scale
Phase 3 trials enroll 1,000 to 3,000 participants and serve as the definitive test. These studies confirm effectiveness, compare the new drug against existing treatments or placebos, monitor side effects across a larger and more diverse population, and collect the safety information needed for labeling. Phase 3 data forms the backbone of the application a company submits to the FDA when seeking approval. These are the largest, longest, and most expensive trials in the process.
Phase 4: After Approval
Clinical development doesn’t fully end when a drug hits the market. Phase 4 studies track a drug’s safety and effectiveness in the general population, where patients are far more varied than those in controlled trials. Rare side effects that occur in fewer than 1 in 3,000 to 5,000 patients are unlikely to surface during pre-approval testing and may only emerge once large numbers of people are using the drug in the real world. Phase 4 data can lead to updated safety labels, new dosing recommendations, boxed warnings, or in rare cases, a drug being pulled from the market entirely. Some Phase 4 studies also explore whether an approved drug might work for conditions it wasn’t originally approved to treat.
How Long It Takes and What It Costs
Clinical development is notoriously slow and expensive. While timelines vary widely by drug and disease area, moving from Phase 1 through approval commonly takes a decade or more when combined with earlier discovery work. The financial burden is equally steep. A 2024 analysis published in JAMA Network Open found that the median cost per newly approved drug was $708 million, and the mean cost reached $1.31 billion, after accounting for the cost of capital and the many drugs that fail along the way. Strip out those adjustments and look only at direct trial costs, and the median drops to about $150 million per drug. Either way, the figures reflect a process where failure is far more common than success, and the cost of every failed compound gets effectively absorbed into the price of the ones that make it through.
Participant Safety and Ethical Standards
Every clinical trial operates under a framework called Good Clinical Practice, or GCP. Rooted in the Declaration of Helsinki, GCP’s core principle is that the rights, safety, and well-being of trial participants come before the interests of science or society. Trials must be scientifically sound, described in clear protocols, and designed so that the level of oversight matches the level of risk to participants.
Institutional Review Boards (IRBs) serve as the primary safeguard. These independent committees review the trial protocol, informed consent materials, and investigator qualifications before a study can begin. They also conduct ongoing reviews at intervals based on how risky the trial is, ensuring that new safety information is acted on throughout the study. No legitimate clinical trial proceeds without IRB approval.
Medical Devices Follow a Different Path
Clinical development isn’t limited to drugs. Medical devices go through their own process, though the regulatory pathway differs. Devices that pose significant risk to patients require an Investigational Device Exemption (IDE) from the FDA before clinical studies can begin, along with IRB approval at each institution involved. Like an IND, an IDE application is considered approved 30 days after the FDA receives it unless the agency says otherwise.
Lower-risk devices have a simpler path. If a device is deemed nonsignificant risk, it needs only IRB approval to begin clinical testing, with no separate FDA submission required. Certain categories are exempt from IDE regulations altogether, including legally marketed devices used according to their labeling, noninvasive diagnostic devices, and devices intended solely for veterinary use or laboratory animal research.
How Decentralized Trials Are Changing the Process
Traditionally, clinical development required participants to travel repeatedly to research hospitals or specialized clinics. Decentralized clinical trials are reshaping that model by allowing trial activities to happen in participants’ homes or local facilities. Wearable devices and at-home measuring tools collect continuous, real-time data on a patient’s condition, providing a more accurate picture of disease progression than periodic clinic visits ever could.
These approaches also address one of clinical development’s most persistent problems: getting enough participants. Decentralized designs improve recruitment and retention by reducing the travel burden, and they bring in patients from rural or underserved areas who would otherwise be excluded. Electronic informed consent with multimedia elements, telemedicine visits, and mobile units that can administer treatments or collect samples at local pharmacies are all becoming standard tools. The field is increasingly moving away from tacking digital solutions onto traditional trial designs and instead building decentralized elements into trials from the start.